{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/rgnx-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/rgnx-stock-analysis/data.json",
 "title": "REGENXBIO (RGNX) Stock Forecast & Price Target (2026)",
 "description": "Regenxbio Inc. (RGNX) stock: Healthcare, Biotechnology. $576M market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Regenxbio Inc. (RGNX)",
 "published": "2026-07-22T09:31:30+00:00",
 "modified": "2026-09-10T11:32:08.212+00:00",
 "generated": "2026-09-11T21:01:49.812Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "RGNX",
  "name": "Regenxbio Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Biotechnology",
  "country": "United States",
  "website": "https://www.regenxbio.com"
 },
 "quote": {
  "price": 8.55,
  "previousClose": 8.73,
  "change": -0.18,
  "changePercent": -2.12,
  "open": 8.54,
  "high": 8.77,
  "low": 8.49,
  "volume": 15785,
  "averageVolume": 1026068,
  "marketCap": 576295166,
  "fiftyTwoWeekHigh": 16.19,
  "fiftyTwoWeekLow": 5.455,
  "marketOpen": false,
  "asOf": "2026-09-10T11:31:55.000Z"
 },
 "statistics": {
  "pe": -2.316489371847599,
  "eps": -3.79,
  "dividendYield": 0,
  "beta": 0.933,
  "priceToSales": 3.306675,
  "priceToBook": 6.596226,
  "revenueTtm": 174482000,
  "grossMargin": 0.9903535489126913,
  "returnOnEquity": -1.3763299
 },
 "technicals": {
  "rsi": 26.77,
  "macd": -0.45,
  "sma50": 10.86,
  "sma200": 10.3,
  "rsiSignal": "Oversold",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 77,
  "consensus": "Buy",
  "fairValue": 19,
  "analystTarget": 19,
  "analystCount": 11,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-10T11:31:55.000Z",
  "priceAtAnalysis": 8.545,
  "volatility": {
   "daily": 6.34,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 8.37,
  "aggressiveEntry": 8.55,
  "stopLoss": 7.5,
  "stopLossPercent": 10.46,
  "targets": [
   8.79,
   9.21,
   9.63
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 4.53,
    "base": 8.6,
    "upside90th": 16.32
   },
   {
    "year": 2028,
    "downside10th": 3.49,
    "base": 8.65,
    "upside90th": 21.41
   },
   {
    "year": 2029,
    "downside10th": 2.87,
    "base": 8.7,
    "upside90th": 26.4
   },
   {
    "year": 2030,
    "downside10th": 2.43,
    "base": 8.76,
    "upside90th": 31.54
   },
   {
    "year": 2031,
    "downside10th": 2.1,
    "base": 8.81,
    "upside90th": 36.92
   },
   {
    "year": 2032,
    "downside10th": 1.84,
    "base": 8.86,
    "upside90th": 42.59
   },
   {
    "year": 2033,
    "downside10th": 1.64,
    "base": 8.92,
    "upside90th": 48.59
   },
   {
    "year": 2034,
    "downside10th": 1.46,
    "base": 8.97,
    "upside90th": 54.96
   },
   {
    "year": 2035,
    "downside10th": 1.32,
    "base": 9.03,
    "upside90th": 61.72
   },
   {
    "year": 2036,
    "downside10th": 1.2,
    "base": 9.08,
    "upside90th": 68.9
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "RGNX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$8.54",
    "Day Range": "$8.49 to $8.77",
    "Prev Close": "$8.73",
    "Volume": "15.8K",
    "52-Week Range": "$5.46 to $16.19",
    "Market Cap": "$576.30M"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, RGNX trades at 3.31x, -21% versus the sector average of 4.20x."
   ]
  },
  {
   "id": "financials",
   "title": "RGNX Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, RGNX beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "RGNX Analysis",
   "text": [
    "Regenxbio Inc. (RGNX) is currently trading below its key moving averages, with its price below the 50-day SMA of $10.86 and the 200-day SMA of $10.30. The Relative Strength Index (RSI) is at 26.77, indicating an oversold condition, which historically can precede a price reversal. The Moving Average Convergence Divergence (MACD) is negative at -0.45, suggesting bearish momentum, but the oversold RSI may offer a near-term support. Volume on the latest trading day was 1.41 million shares, exceeding the average volume of 1.14 million shares by 23.4%, indicating increased investor interest. Key support levels are near the current price, with the oversold RSI suggesting that further downside may be limited. The stock's proximity to its 52-week low, coupled with the oversold technicals, presents a potential entry point for investors anticipating a rebound.",
    "Regenxbio Inc. reported an EPS of $0.43 versus an estimate of -$0.11 for Q2 2026, a 490.91% surprise, indicating potential operational improvements.",
    "Analysts forecast revenue growth of 28.00% for the next quarter and 29.00% for the next year, suggesting a turnaround in sales performance.",
    "The RSI is at 26.77, indicating the stock is oversold and may be due for a technical rebound.",
    "Insiders have sold $1.5 million in stock versus purchased $949,381, indicating a moderate sell signal from management.",
    "The company currently has a negative EPS of -$3.79 and has shown inconsistent profitability in recent quarters.",
    "Regenxbio Inc. (RGNX) is expected to see a positive trajectory over the next 6-12 months, driven by strong revenue growth projections and a significant upside to the median analyst price target of $19.00. The company's ability to beat earnings estimates, as seen in the latest report, coupled with an oversold technical condition, suggests potential for a rebound from the current price of $8.73. The thesis could be altered by continued insider selling pressure or a failure to meet forward revenue estimates, which currently project substantial growth. However, the strong analyst conviction and the significant gap between the current price and target price present a compelling risk-reward profile for investors willing to look past short-term technical weakness and earnings volatility."
   ],
   "lists": {
    "ProTips": [
     "Regenxbio Inc. (RGNX) is trading in oversold territory with an RSI of 26.77, suggesting a potential near-term bounce. Consider dollar-cost averaging into positions on any further dips.",
     "The median analyst target price for RGNX is $19.00, implying over 117% upside from the current price, making it an attractive speculative buy.",
     "Monitor insider transactions closely; while recent activity shows net selling, a shift towards net buying could signal renewed management confidence."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong EPS Beat in Latest Earnings",
     "text": "Regenxbio Inc. reported an EPS of $0.43 versus an estimate of -$0.11 for Q2 2026, a 490.91% surprise, indicating potential operational improvements.",
     "source": "Company Earnings Release"
    },
    {
     "type": "Bullish",
     "title": "Positive Revenue Growth Projections",
     "text": "Analysts forecast revenue growth of 28.00% for the next quarter and 29.00% for the next year, suggesting a turnaround in sales performance.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Bullish",
     "title": "Oversold Technical Conditions",
     "text": "The RSI is at 26.77, indicating the stock is oversold and may be due for a technical rebound.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insiders have sold $1.5 million in stock versus purchased $949,381, indicating a moderate sell signal from management.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Negative EPS and Volatile Profitability",
     "text": "The company currently has a negative EPS of -$3.79 and has shown inconsistent profitability in recent quarters.",
     "source": "Fundamental Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Regenxbio Inc. (RGNX) exhibits a negative P/E ratio due to its negative EPS of -$3.79, making traditional valuation metrics like P/E and PEG ratios inapplicable. The company's revenue growth has been volatile, with a reported 405.7% year-over-year growth, but current quarter estimates show a -44.00% year-over-year decline. However, forward-looking estimates are more optimistic, with next year's revenue projected to grow by 29.00% to $217.1 million. Profitability remains a concern, as indicated by the negative EPS. The company's balance sheet strength is not detailed, but the significant revenue growth reported in the past suggests underlying business expansion. The current stock price of $8.73 is substantially below the median analyst price target of $19.00, indicating that the market may be undervaluing the company's long-term growth prospects.",
    "Regenxbio Inc. (RGNX) demonstrated a significant EPS beat in its most recent earnings report on August 6, 2026, reporting $0.43 against an estimate of -$0.11, a 490.91% surprise. Despite this strong beat, the stock price declined by 4.96%. Prior earnings reports show mixed performance, with a substantial miss in Q2 2026 (-$1.72 actual vs. -$1.41 estimate) and Q1 2026 (-$1.30 actual vs. -$0.84 estimate), but a beat in Q4 2025 ($1.87 actual vs. $1.61 estimate). This earnings history indicates earnings volatility, but the most recent positive surprise warrants attention.",
    "Regenxbio Inc. (RGNX) faces significant risks, including its current technical weakness with the stock trading below key moving averages and a moderate insider sell signal, with total sales exceeding purchases by approximately $570,000. The company's negative EPS and volatile revenue growth also present fundamental challenges. Also, the recent stock price reaction to a significant EPS beat suggests that positive earnings news may not be translating into immediate stock appreciation, highlighting potential investor skepticism or broader market pressures."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "576.30M"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-3.79"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "16.19"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "5.46"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($10.86) above the 200-day SMA ($10.30), price is trading below the 50-day SMA, RSI at 26.8 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "26.77"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-0.45"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "10.86"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "10.30"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.31",
    "Correlation with Nasdaq 100 (QQQ)": "+0.30",
    "Correlation with Bitcoin (BTC)": "+0.05",
    "Correlation with Gold (XAU)": "+0.08"
   }
  },
  {
   "id": "trade-plans",
   "title": "RGNX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (26.8) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$8.793",
    "TARGET 2": "$9.212",
    "TARGET 3": "$9.630",
    "STOP LOSS": "$7.498"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-8.45%",
    "Average Feb return": "+0.52%",
    "Average Mar return": "-1.47%",
    "Average Apr return": "+5.77%",
    "Average May return": "-7.15%",
    "Average Jun return": "+11.71%",
    "Average Jul return": "-3.95%",
    "Average Aug return": "-0.99%",
    "Average Sep return": "+6.74%",
    "Average Oct return": "-2.15%",
    "Average Nov return": "+11.60%",
    "Average Dec return": "-2.02%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "6.34%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in RGNX in September 2016 would be worth about $6,443 today, compared with about $35,241 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RGNX today could grow to about $10,628 by 2036 in the base case, with a bull case near $80,633 and a bear case around $1,401. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "RGNX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $8.76 for RGNX by 2030 in the base case, from $8.55 today (1.0x over 4 years). The downside path ends near $2.43. These are outcomes of a Monte Carlo simulation run on RGNX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using RGNX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "RGNX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$4.53",
        "$8.60",
        "$16.32"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$3.49",
        "$8.65",
        "$21.41"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$2.87",
        "$8.70",
        "$26.40"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$2.43",
        "$8.76",
        "$31.54"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$2.10",
        "$8.81",
        "$36.92"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$1.84",
        "$8.86",
        "$42.59"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$1.64",
        "$8.92",
        "$48.59"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$1.46",
        "$8.97",
        "$54.96"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$1.32",
        "$9.03",
        "$61.72"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$1.20",
        "$9.08",
        "$68.90"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "ZTS Zoetis Inc. NYSE $72.96 +0.1372%",
     "url": "https://clearank.com/stock/zts-stock-analysis/"
    },
    {
     "text": "CI The Cigna Group NYSE $278.36 -0.9095%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    },
    {
     "text": "JNJ Johnson & Johnson NYSE $265.63 -0.2703%",
     "url": "https://clearank.com/stock/johnson-johnson-jnj/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $43.10 -4.14%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $417.37 -1.06%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "NTRA Natera, Inc. NASDAQ $326.14 -1.26%",
     "url": "https://clearank.com/stock/natera-ntra/"
    },
    {
     "text": "ABT Abbott Laboratories NYSE $103.36 -1.78%",
     "url": "https://clearank.com/stock/abbott-laboratories-abt/"
    },
    {
     "text": "DHR Danaher Corp. NYSE $200.53 -2.11%",
     "url": "https://clearank.com/stock/dhr-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "XAG/USD vs XPT/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/silver-vs-platinum/"
    },
    {
     "text": "XLK vs QQQ Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/xlk-vs-qqq/"
    },
    {
     "text": "SCHD vs VIG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/schd-vs-vig/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "RGNX Insider Trading Analysis",
   "facts": {
    "Bought": "$949.4K",
    "Sold": "$1.5M",
    "Insiders": "15",
    "Avg Transaction": "$274.3K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in RGNX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Nov 2, 2018",
       "cells": [
        "VASISTA VITTAL Chief Financial Officer",
        "Sell",
        "73.4K",
        "$5.2M"
       ]
      },
      {
       "label": "Dec 23, 2021",
       "cells": [
        "FOX ALLAN MARK Director",
        "Sell",
        "112.9K",
        "$3.9M"
       ]
      },
      {
       "label": "Oct 16, 2018",
       "cells": [
        "SIMPSON CURRAN M Officer",
        "Sell",
        "62.3K",
        "$3.8M"
       ]
      },
      {
       "label": "Feb 11, 2020",
       "cells": [
        "SIMPSON CURRAN M Chief Technology Officer",
        "Sell",
        "57.0K",
        "$2.9M"
       ]
      },
      {
       "label": "Feb 5, 2019",
       "cells": [
        "SIMPSON CURRAN M Chief Technology Officer",
        "Sell",
        "43.8K",
        "$2.2M"
       ]
      },
      {
       "label": "Sep 17, 2021",
       "cells": [
        "FOX ALLAN MARK Director",
        "Sell",
        "48.2K",
        "$2.2M"
       ]
      },
      {
       "label": "Nov 16, 2018",
       "cells": [
        "SIMPSON CURRAN M Officer",
        "Sell",
        "32.9K",
        "$2.1M"
       ]
      },
      {
       "label": "Nov 20, 2018",
       "cells": [
        "BESHAR LUKE M Director",
        "Sell",
        "33.3K",
        "$2.0M"
       ]
      },
      {
       "label": "Sep 14, 2021",
       "cells": [
        "MILLS KENNETH THOMAS Chief Executive Officer",
        "Sell",
        "38.0K",
        "$1.7M"
       ]
      },
      {
       "label": "Dec 11, 2020",
       "cells": [
        "VASISTA VITTAL Chief Financial Officer",
        "Sell",
        "37.5K",
        "$1.5M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Regenxbio+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Regenxbio Inc.'s stock forecast for 2030?",
   "answer": "Regenxbio Inc.'s stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $8.95, with a downside scenario of $2.48 and an upside scenario of $32.22. These figures are statistical outcomes, not guaranteed price targets."
  },
  {
   "question": "Is Regenxbio Inc. stock a buy right now?",
   "answer": "Regenxbio Inc. (RGNX) is currently rated a Buy with a consensus score of 77. The median analyst target price is $19.00, offering over 117% upside from the current price of $8.73, and the stock is in oversold territory technically."
  },
  {
   "question": "What is Regenxbio Inc.'s current valuation?",
   "answer": "Regenxbio Inc. has a negative P/E ratio due to its negative EPS of -$3.79. The current stock price of $8.73 is significantly below the median analyst price target of $19.00, suggesting it may be undervalued relative to analyst expectations."
  },
  {
   "question": "How did Regenxbio Inc. perform in its latest earnings report?",
   "answer": "In its latest earnings report on August 6, 2026, Regenxbio Inc. reported an EPS of $0.43, significantly beating the estimate of -$0.11 by 490.91%, although the stock price declined by 4.96%."
  },
  {
   "question": "What are the key risks for Regenxbio Inc.?",
   "answer": "Key risks for Regenxbio Inc. include its current technical weakness, a moderate insider sell signal, negative EPS, and volatile revenue growth. The stock's reaction to positive earnings also highlights potential investor skepticism."
  },
  {
   "question": "What is Regenxbio Inc.'s revenue growth outlook?",
   "answer": "While the current quarter's revenue is estimated to decline 44.00% year-over-year, Regenxbio Inc.'s outlook is positive for the next quarter and year, with projected revenue growth of 28.00% and 29.00% respectively."
  },
  {
   "question": "Does Regenxbio Inc. pay a dividend?",
   "answer": "Regenxbio Inc. does not currently pay a dividend, with a reported dividend yield and rate of 0%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "ZTS",
    "name": "Zoetis Inc. NYSE",
    "price": "$72.96",
    "change": "+0.1372%",
    "url": "https://clearank.com/stock/zts-stock-analysis/"
   },
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$278.36",
    "change": "-0.9095%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "JNJ",
    "name": "Johnson & Johnson NYSE",
    "price": "$265.63",
    "change": "-0.2703%",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$43.10",
    "change": "-4.14%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$417.37",
    "change": "-1.06%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "NTRA",
    "name": "Natera, Inc. NASDAQ",
    "price": "$326.14",
    "change": "-1.26%",
    "url": "https://clearank.com/stock/natera-ntra/"
   },
   {
    "ticker": "ABT",
    "name": "Abbott Laboratories NYSE",
    "price": "$103.36",
    "change": "-1.78%",
    "url": "https://clearank.com/stock/abbott-laboratories-abt/"
   },
   {
    "ticker": "DHR",
    "name": "Danaher Corp. NYSE",
    "price": "$200.53",
    "change": "-2.11%",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "XAG/USD vs XPT/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/silver-vs-platinum/"
   },
   {
    "ticker": "XLK vs QQQ Comparison",
    "name": "",
    "url": "https://clearank.com/compare/xlk-vs-qqq/"
   },
   {
    "ticker": "SCHD vs VIG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/schd-vs-vig/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   },
   {
    "ticker": "AME",
    "text": "AMETEK, Inc.",
    "url": "https://clearank.com/stock/ame-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 9.39%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.23%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "AERO/USD",
    "text": "↑ 8.90%",
    "url": "https://clearank.com/crypto/aero-usd-crypto-analysis/"
   },
   {
    "ticker": "HUT",
    "text": "↑ 8.77%",
    "url": "https://clearank.com/stock/hut-stock-analysis/"
   },
   {
    "ticker": "MRNA",
    "text": "↑ 8.44%",
    "url": "https://clearank.com/stock/moderna-mrna/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "MRNA",
    "text": "Moderna, Inc.",
    "url": "https://clearank.com/stock/moderna-mrna/"
   },
   {
    "ticker": "REGN",
    "text": "Regeneron Pharmaceuticals",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "REPL",
    "text": "Replimune",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "text": "Recursion",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "text": "Viking Therapeutics Inc",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/RGNX-regenxbio-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/RGNX-regenxbio-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "REGENXBIO (RGNX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/rgnx-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/rgnx-stock-analysis/",
        "name": "REGENXBIO (RGNX) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/rgnx-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/rgnx-stock-analysis/",
     "name": "REGENXBIO (RGNX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-22T09:31:30+00:00",
     "dateModified": "2026-09-10T11:32:08+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/RGNX-regenxbio-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/rgnx-stock-analysis/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "REGENXBIO (RGNX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-22T09:31:30+00:00",
     "dateModified": "2026-09-10T11:32:08+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Regenxbio Inc. (RGNX) stock: Healthcare, Biotechnology. $576M market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "REGENXBIO (RGNX) Stock Forecast & Price Target (2026)",
     "@id": "https://clearank.com/stock/rgnx-stock-analysis/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/rgnx-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/RGNX-regenxbio-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/rgnx-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Regenxbio Inc. (RGNX)",
   "tickerSymbol": "RGNX",
   "url": "https://clearank.com/stock/rgnx-stock-analysis/",
   "description": "AI-powered financial analysis for Regenxbio Inc. (RGNX) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NASDAQ",
   "offers": {
    "@type": "Offer",
    "price": 8.545,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Regenxbio Inc.'s stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regenxbio Inc.'s stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $8.95, with a downside scenario of $2.48 and an upside scenario of $32.22. These figures are statistical outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Regenxbio Inc. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regenxbio Inc. (RGNX) is currently rated a Buy with a consensus score of 77. The median analyst target price is $19.00, offering over 117% upside from the current price of $8.73, and the stock is in oversold territory technically."
     }
    },
    {
     "@type": "Question",
     "name": "What is Regenxbio Inc.'s current valuation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regenxbio Inc. has a negative P/E ratio due to its negative EPS of -$3.79. The current stock price of $8.73 is significantly below the median analyst price target of $19.00, suggesting it may be undervalued relative to analyst expectations."
     }
    },
    {
     "@type": "Question",
     "name": "How did Regenxbio Inc. perform in its latest earnings report?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "In its latest earnings report on August 6, 2026, Regenxbio Inc. reported an EPS of $0.43, significantly beating the estimate of -$0.11 by 490.91%, although the stock price declined by 4.96%."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks for Regenxbio Inc.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks for Regenxbio Inc. include its current technical weakness, a moderate insider sell signal, negative EPS, and volatile revenue growth. The stock's reaction to positive earnings also highlights potential investor skepticism."
     }
    },
    {
     "@type": "Question",
     "name": "What is Regenxbio Inc.'s revenue growth outlook?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "While the current quarter's revenue is estimated to decline 44.00% year-over-year, Regenxbio Inc.'s outlook is positive for the next quarter and year, with projected revenue growth of 28.00% and 29.00% respectively."
     }
    },
    {
     "@type": "Question",
     "name": "Does Regenxbio Inc. pay a dividend?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Regenxbio Inc. does not currently pay a dividend, with a reported dividend yield and rate of 0%."
     }
    }
   ]
  }
 ]
}